Researchers at the University of Copenhagen – The Faculty of Health and Medical Sciences found that activating a specialized group of neurons within the brainstem of mice restored full movement function in mice with symptoms of Parkinson’s disease.
Researchers have unlocked a key mechanism behind the genetic variant which could prove hopeful for new treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
The U.S. Food and Drug Administration sent Denali Therapeutics a formal clinical hold letter regarding the investigational new drug (IND) application for the company’s Alzheimer’s drug candidate DNL919.
Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through the advancement of a novel immuno-neurology treatment approach.
Cambridge, Mass.-based QurAlis Corporation increased the company’s financial footing following a $42 million Series A financing round that will be used to support the continued development of therapeutic drugs for ALS and genetically related frontotemporal dementia (FTD).
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
